Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
OCUL
OCUL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OCUL News
Wall Street Analysts Adjust GE Stock Ratings
Mar 03 2026
Benzinga
OCUL Stock 52-Week High and Low Analysis
Mar 02 2026
NASDAQ.COM
Ocular Therapeutix Shares Drop Amid Inflation Concerns
Feb 28 2026
Yahoo Finance
Analysis of Potential and Risks in Small-Cap Stocks
Feb 27 2026
Yahoo Finance
iShares Expanded Tech-Software ETF Underperforms
Feb 23 2026
NASDAQ.COM
Ocular Therapeutix to Present AXPAXLI Trial Results at Macula Society Meeting
Feb 23 2026
NASDAQ.COM
Investigation into Ocular Therapeutix Investor Claims
Feb 18 2026
Globenewswire
U.S. Stocks Mostly Lower, Nasdaq Drops Over 50 Points
Feb 17 2026
Benzinga
Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment
Feb 17 2026
Benzinga
OCULAR THERAPEUTIX STOCK PLUMMETS 23.5% FOLLOWING RELEASE OF LATE-STAGE EYE DISEASE TRIAL RESULTS
Feb 17 2026
moomoo
Ocular Therapeutix Releases Axpaxli Trial Data, Stock Drops 22%
Feb 17 2026
seekingalpha
U.S. Stock Futures Fluctuate Amid Government Shutdown Impact
Feb 17 2026
Benzinga
ZIM Integrated Shipping Shares Surge 36% Following Acquisition Deal
Feb 17 2026
seekingalpha
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
Feb 17 2026
Benzinga
Hapag-Lloyd Acquires ZIM for $4.2 Billion Amid Market Volatility
Feb 17 2026
stocktwits
Ocular Therapeutix Set to Release Axpaxli Phase 3 Trial Results
Feb 17 2026
stocktwits
Show More News
